FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to biotechnology, particularly to such binding elements specific for IgE as antibody molecules or its antigen-binding fragments.
EFFECT: antibody or its versions specific for IgE are effective for treating IgE-associated disorders, such as allergy and asthma.
17 cl, 17 dwg, 8 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMANISED ANTIBODY AND ANTIGENBINDING FRAGMENT (Fab), WHICH BINDS WITH HUMAN INTERFERON-γ, DNA FRAGMENTS CODING CLAIMED ANTIBODY AND ANTIGEN-BINDING FRAGMENT, CELL, TRANSFORMED BY DNA FRAGMENT, AND METHOD OF OBTAINING CLAIMED ANTIBODY AND ANTIGEN-BINDING FRAGMENT | 2013 |
|
RU2539752C2 |
| ANTIBODY AGAINST B7-H3, ITS ANTIGEN-BINDING FRAGMENT AND THEIR MEDICAL USE | 2018 |
|
RU2765306C2 |
| METHOD AND OBTAINED HUMAN ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT FOR INHIBITING HUMAN TNF ACTIVITY, APPLYING THE OBTAINED HUMAN ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT AS INGREDIENT FOR PRODUCING MEDICAMENT | 1997 |
|
RU2270030C2 |
| ANTI-IGE ANTIBODIES | 2017 |
|
RU2816207C2 |
| RECOVERED HUMAN ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT (VERSIONS), METHOD OF TREATING hTNFα-MEDIATED DISEASES WITH MEDIATION THEREOF (VERSIONS), PHARMACEUTICAL COMPOSITION, RECOMBINANT HUMAN ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT, RECOVERED NUCLEIC ACID (VERSIONS) | 2005 |
|
RU2458704C9 |
| HUMAN IL-13 ANTIBODY MOLECULES | 2004 |
|
RU2387667C2 |
| ANTIBODY AGAINST IL-5, ITS ANTIGEN-BINDING FRAGMENT AND ITS MEDICAL USE | 2018 |
|
RU2772716C2 |
| STRUCTURED ANTI-TGF-BETA ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS | 2014 |
|
RU2681502C2 |
| HUMANISED 5D3HU ANTIBODY BINDING TO THE PRAME TUMOUR ANTIGEN, DNA FRAGMENTS ENCODING SAID ANTIBODY, AND ANTIGEN-BINDING FRAGMENT OF THE ANTIBODY | 2020 |
|
RU2761876C1 |
| ANTIBODIES WITHOUT Fc-FRAGMENT INCLUDING TWO FAB-FRAGMENT AND METHODS OF APPLICATION | 2012 |
|
RU2617970C2 |
